Show simple item record

dc.contributor.authorJenks, AD
dc.contributor.authorVyse, S
dc.contributor.authorWong, JP
dc.contributor.authorKostaras, E
dc.contributor.authorKeller, D
dc.contributor.authorBurgoyne, T
dc.contributor.authorShoemark, A
dc.contributor.authorTsalikis, A
dc.contributor.authorde la Roche, M
dc.contributor.authorMichaelis, M
dc.contributor.authorCinatl, J
dc.contributor.authorHuang, PH
dc.contributor.authorTanos, BE
dc.date.accessioned2018-06-08T08:14:33Z
dc.date.issued2018-06-05
dc.identifier.citationCell reports, 2018, 23 (10), pp. 3042 - 3055
dc.identifier.issn2211-1247
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1756
dc.identifier.eissn2211-1247
dc.identifier.doi10.1016/j.celrep.2018.05.016
dc.description.abstractPrimary cilia are microtubule-based organelles that detect mechanical and chemical stimuli. Although cilia house a number of oncogenic molecules (including Smoothened, KRAS, EGFR, and PDGFR), their precise role in cancer remains unclear. We have interrogated the role of cilia in acquired and de novo resistance to a variety of kinase inhibitors, and found that, in several examples, resistant cells are distinctly characterized by an increase in the number and/or length of cilia with altered structural features. Changes in ciliation seem to be linked to differences in the molecular composition of cilia and result in enhanced Hedgehog pathway activation. Notably, manipulating cilia length via Kif7 knockdown is sufficient to confer drug resistance in drug-sensitive cells. Conversely, targeting of cilia length or integrity through genetic and pharmacological approaches overcomes kinase inhibitor resistance. Our work establishes a role for ciliogenesis and cilia length in promoting cancer drug resistance and has significant translational implications.
dc.formatPrint
dc.format.extent3042 - 3055
dc.languageeng
dc.language.isoeng
dc.publisherCELL PRESS
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectCell Line, Tumor
dc.subjectCilia
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectProtein Kinase Inhibitors
dc.subjectSignal Transduction
dc.subjectUp-Regulation
dc.subjectOrganogenesis
dc.subjectDrug Resistance, Neoplasm
dc.subjectModels, Biological
dc.subjectHedgehog Proteins
dc.titlePrimary Cilia Mediate Diverse Kinase Inhibitor Resistance Mechanisms in Cancer.
dc.typeJournal Article
dcterms.dateAccepted2018-05-03
rioxxterms.versionofrecord10.1016/j.celrep.2018.05.016
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2018-06
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCell reports
pubs.issue10
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Protein Networks
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Protein Networks
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.publication-statusPublished
pubs.volume23
pubs.embargo.termsNo embargo
icr.researchteamProtein Networks
icr.researchteamMolecular and Systems Oncology
dc.contributor.icrauthorTsalikis, Athanasios
dc.contributor.icrauthorHuang, Paul


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0